Impel Pharmaceuticals to Report First Quarter 2022 Financial Results on Monday, May 16, 2022
Impel Pharmaceuticals Inc. (NASDAQ: IMPL) will host a live webcast on May 16, 2022, at 8:30 a.m. ET to report its Q1 2022 financial results and provide a business update. The call can be accessed via phone or through a live webcast on their investor website. Impel focuses on developing therapies for unmet medical needs, particularly in the central nervous system. Their approved product, Trudhesa™, is a nasal spray for migraine treatment, and they are developing additional treatments for autism-related agitation and Parkinson’s disease.
- None.
- None.
SEATTLE, May 09, 2022 (GLOBE NEWSWIRE) -- Impel Pharmaceuticals Inc. (NASDAQ: IMPL), a commercial-stage pharmaceutical company developing transformative therapies for people suffering from diseases with high unmet medical needs, with an initial focus on the central nervous system, today announced it will host a live webcast on Monday, May 16, 2022, at 8:30 a.m. ET to report its first quarter 2022 financial results and provide a business update.
The conference call may be accessed by dialling 877-295-2648 (domestic) or 470-495-9487 (international) and referring to conference ID 2468863. A live webcast of the event will be available on the Investors section of the Impel Pharmaceuticals website at https://investors.impelpharma.com/. A replay of the webcast and accompanying slides will be available on the Impel Pharmaceuticals website following the event.
About Impel Pharmaceuticals Inc.
Impel Pharmaceuticals Inc. is a commercial-stage biopharmaceutical company developing transformative therapies for people suffering from diseases with high unmet medical needs, with an initial focus on diseases of the central nervous system. Impel offers and is developing treatments that pair its proprietary Precision Olfactory Delivery (POD®) technology with well-established therapeutics. In addition to Trudhesa™ (dihydroergotamine mesylate) nasal spray, which is approved in the United States for the acute treatment of migraine with or without aura in adults, Impel is also developing INP105 for the acute treatment of agitation and aggression in patients with autism, and INP107 for OFF episodes in Parkinson’s disease.
For additional information about Impel, please visit www.ImpelPharma.com
Contact:
Media Relations:
Melyssa Weible
Elixir Health Public Relations
Phone: (1) 201-723-5805
Email: mweible@elixirhealthpr.com
Investor Relations
Christina Tartaglia
Stern Investor Relations
Phone: 212-362-1200
Email: christina.tartaglia@sternir.com
FAQ
When will Impel Pharmaceuticals announce its Q1 2022 financial results?
What is the focus of Impel Pharmaceuticals?
How can I access the Impel Pharmaceuticals Q1 2022 results webcast?
What is Trudhesa™ and its indication?
